CALENDAR:
Save the date: Dine Out for Lupus - May 14, 2013.
Simply dine out at a participating restaurant (more information coming soon), and your restaurant will donate part of the proceeds to LFNC and lupus research.
December 18
2012 Lupus Treatment and Research Update (mini-conference), Women's Building, San Francisco
Click here to see our full calendar of events and add them to your own calendar here!
Benlysta Webcast/Teleconference Series
Presented by Human Genome Sciences/GlaxoSmithKline
Nov 28
8pm ET
Tune in from home!
A different lupus-related topic will be addressed each month such as Benlysta and the infusion process, how to strengthen communications with your doctors, tips for managing lupus, and information about financial assistance.
To register for these free events, call 1-877-423-6597
|
|
35 years. $35,000. Help us get there!
|
Information contained in this e-Newsletter should not be considered a substitute for professional diagnosis, treatment or management of S.L.E. and symptoms by a physician.
Missed a previous issue of this e-Newsletter?
You can now view our ARCHIVES.
Editor: Spandan Chakrabarti
|
|
LFNC is an active partner in
|
|
Connect with us on
via "Lupus Online"
|
LFNC's Social Media Program is funded through a generous grant from THE HENRY L. GUENTHER FOUNDATION GEORGE H. SANDY FOUNDATION GLAXOSMITHKLINE |
|
|
|
You are receiving this newsletter because you have subscribed or have participated in our programs or events. We respect your time and privacy. If you prefer not to continue receiving the newsletter, you can click on the "safe unsubscribe" button below. We hope, however, that you will opt to remain on our newsletter list for important information and life-saving tips that you or someone you know may benefit from now or in the future.
|
|
American College of Rheumatology Presents Lupus Findings in Annual Meeting
This past year brought us exciting news in Lupus research - from research to find the cause of Lupus to an acceleration of Lupus drug development. This Thanksgiving week, we are profoundly grateful to those in the medical community who carry on Lupus Research, inching us closer to bridging the gap between life with and without Lupus.
Our national research partners at the Lupus Research Institute report on the highlights of Lupus news presented at the annual scientific meeting of the American College of Rheumatology:
- Biopharmaceutical company Immunomedics, Inc. announced that lupus patients receiving the investigational drug epratuzumab reported clinically meaningful improvements in health-related quality of life that were sustained over approximately 4 years of treatment. This is the second presentation at the meeting that demonstrated clinical benefits of epratuzumab treatment as reported by patients in the ALLEVIATE extension study.
- Genetic changes that protected their ancestors against parasites carried by flies may partly explain why African-Americans with lupus are far more likely to develop end-stage kidney disease than those of European descent. This was the conclusion of a study presented by researchers from University of Alabama at Birmingham.
- High levels of an experimental biomarker (BLyS -- B-lymphocyte stimulator) predicted flares among patients with systemic lupus erythematosus, according to an analysispresented at ACR by Michelle Petri, MD of Johns Hopkins University. Over one year, 26% of patients with the lowest levels of the biomarker had a moderate-to-severe disease flare, compared with 45% of those who had the highest levels.
- A new study presented by researchers at Hospital for Special Surgery challenges common beliefs about joint replacement in patients with lupus. Investigators showed that lupus patients undergoing joint replacement surgery experienced fewer side effects than previously thought.
- High rates of systemic lupus erythematosus have been linked to exposure to uranium, according to new research presented by researchers at the University of Cincinnati and Cincinnati Children's Medical Center. The goal of the study was to explain why a higher than normal number of lupus cases were reported in a Ohio community five miles from a former uranium plant. Lead investigator Pai-Yu Lu, MD at Cincinnati Children's Hospital Medical Center explained that the basis for the study was knowing that "lupus patients may be sensitive to sunlight and irradiation, in addition to literature hinting that miners may be at increased risk for developing lupus."
- Idera Pharmaceuticals, Inc. announced they will be starting a Phase 1 trial of an investigational drug for lupus, IMO-8400. IMO-8400 is an antagonist of Toll-like receptors (TLRs) 7, 8 and 9.
|
|
Your 2013 Calendar - with Lupus Facts - are Here! Get Yours Today!
12 Lupus Facts. 12 Adorable Puppies. 12 Months. All of them have come together to make this One Awesome Calendar! Our 2013 desk calendar includes a Lupus Fact every month, along with a picture of one of our Mascot Contest contestant puppies from our Run & Walk this year. 12 adorable four-legged contestants entered, and each of them is featured on one month.
We just got the calendars into the office, and you can order yours right now. Click here to order yours today. Each calendar is only $15, including shipping. |
|
Lupus Patients Wanted for Online Market Research - Make $100
 Fieldwork San Francisco, a national market research firm, is conducting Online Interviews to gather the opinions of Lupus patients. There are no sales involved - the researchers are only interested in participants' opinions.
The interviews will last about 30 minutes, and participants will be compensated $100 for their time. If you would like to participate, please call 415.268.8686 and ask to speak to someone about the Health Conditions Study. When calling, please mention you were referred by the Lupus Foundation of Northern California ($50 per referral will be donated towards LFNC programs and services).
|
|
Join Us at Our Winter Mini-Conference
Maria Dall'Era, M.D., will be headlining our conference. Dr. Dall'Era is an Associate Professor of Clinical Medicine and Director of the Rheumatology Clinical Research Center at the University of California, San Francisco. She is also the Director of the UCSF Lupus Clinic, UCSF Center Director of the Lupus Clinical Trials Consortium (LCTC), and Principal Investigator of the California Lupus Surveillance Project (CLSP). Her talk will focus on the latest treatment strategies and research studies on lupus and will share significant updates from the Annual Scientific Meeting of the American College of Rheumatology to be held in Washington, D.C. in November.
Date and Time:
Tuesday, December 18, 2012, 11 am to 4 pm.
Venue:
The Women's Building, Auditorium
3543 18th Street
San Francisco, CA 94110
Registration fee:
$50 for nurses desiring CEU credits (5 CEU credits)
$30 for non-credit attendees
Current LFNC members are entitled to $10 off registration fee. Box lunch included.
No one will be turned away for inability to pay.
Please click here to register. You may also register by mail or fax by completing this form, or by calling us at 408-954-8600.
Funding support for this conference provided by Amgen, Inc.
|
|
Grand Prize: A Mercedes-Benz C300. Plus Two iPads for Early Birds.
This is a great way to help out the Lupus Foundation and support our work in patient services, education and research, you can start buying tickets right away!
Ticket prices are changing a bit this year: you will be able to buy each ticket for $75, three (3) tickets for $200 and five (5) for $300. In addition to the Mercedes, participants who buy their tickets early will also have the chance to win up to two iPads! Early bird drawings will be held on December 14 and March 15.
|
|
|
|
|
|
|
